| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
Study objectives: We examined the effects of glucocorticoids on airway inflammation and its association with the reversibility of airflow obstruction in response to oral glucocorticoid administration in patients with COPD.
Patients:
Twenty-four male patients with smoking-related stable pulmonary
emphysema without 
1-antitrypsin deficiency and nine
normal healthy volunteers.
Measurements: We measured
the pulmonary function, the inflammatory cells, and the levels of
eosinophil cationic protein (ECP), immunoreactive neutrophil
elastase-1-protease inhibitor (NE-1-PI)
complex, and interleukin (IL)-8 in sputum induced from patients with
pulmonary emphysema in its stable phase before and after treatment with
20 mg oral prednisolone per day for 2 weeks.
Results:
The eosinophil and neutrophil counts and the concentrations of ECP,
NE-1-PI complex, and IL-8 in the sputum were
significantly increased at baseline. The eosinophil count at baseline
was significantly correlated with the reversibility of airflow
obstruction following treatment, and the treatment also significantly
reduced the eosinophil numbers and ECP level in the sputum. In
contrast, the increased neutrophil number and the concentrations of
NE-1-PI complex and IL-8 at baseline did not correlate
with the reversibility and were not affected by treatment.
Conclusions: These findings suggest that the eosinophilic inflammation, not neutrophilic inflammation, in the airway is involved in the reversible part of the airflow obstruction in response to glucocorticoids in patients with pulmonary emphysema.
Key Words: corticosteroid • eosinophil • eosinophil cationic protein • IL-8 • induced sputum • neutrophil • neutrophil elastase • pulmonary emphysema
This article has been cited by other articles:
|
|
 |
|
  R O'Donnell, D Breen, S Wilson, and R Djukanovic Inflammatory cells in the airways in COPD Thorax, May 1, 2006; 61(5): 448 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Fujimoto, M. Yasuo, K. Urushibata, M. Hanaoka, T. Koizumi, and K. Kubo Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease Eur. Respir. J., April 1, 2005; 25(4): 640 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Donohue and J. A. Ohar Effects of Corticosteroids on Lung Function in Asthma and Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2004; 1(3): 152 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.-W. Perng, H.-Y. Huang, H.-M. Chen, Y.-C. Lee, and R.-P. Perng Characteristics of Airway Inflammation and Bronchodilator Reversibility in COPD: A Potential Guide to Treatment Chest, August 1, 2004; 126(2): 375 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Barczyk, E. Sozanska, M. Trzaska, and W. Pierzchala Decreased Levels of Myeloperoxidase in Induced Sputum of Patients With COPD After Treatment With Oral Glucocorticoids Chest, August 1, 2004; 126(2): 389 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-W. Perng, H.-Y. Huang, Y.-C. Lee, and R.-P. Perng Leukotriene Modifier vs Inhaled Corticosteroid in Mild-to-Moderate Asthma: Clinical and Anti-inflammatory Effects Chest, May 1, 2004; 125(5): 1693 - 1699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Tashkin and S. Kesten Long-term Treatment Benefits With Tiotropium in COPD Patients With and Without Short-term Bronchodilator Responses Chest, May 1, 2003; 123(5): 1441 - 1449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A J White, S Gompertz, and R A Stockley Chronic obstructive pulmonary disease * 6: The aetiology of exacerbations of chronic obstructive pulmonary disease Thorax, January 1, 2003; 58(1): 73 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. KHARITONOV and P. J. BARNES Exhaled Markers of Pulmonary Disease Am. J. Respir. Crit. Care Med., June 1, 2001; 163(7): 1693 - 1722. [Full Text] [PDF]
|
|
|
|
|
|
P MAESTRELLI, L RICHELDI, M MORETTI, and L M FABBRI Analysis of sputum in COPD Thorax, June 1, 2001; 56(6): 420 - 422. [Full Text]
|
|
|
|
|
|
A. PAPI, M. ROMAGNOLI, S. BARALDO, F. BRACCIONI, I. GUZZINATI, M. SAETTA, A. CIACCIA, and L. M. FABBRI Partial Reversibility of Airflow Limitation and Increased Exhaled NO and Sputum Eosinophilia in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., November 1, 2000; 162(5): 1773 - 1777. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
